Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2021-03-02 Management Reports
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Management Reports Classification · 100% confidence The document is titled 'FORM 51-102F1 SAINT JEAN CARBON INC. MANAGEMENT DISCUSSION & ANALYSIS' and is for the quarter ended October 31, 2020. It contains detailed discussion and analysis of the company's financial condition, results of operations, business description, and financial data tables for quarterly and annual periods. The text explicitly states it is a Management Discussion and Analysis (MD&A) document, which is a detailed explanation of financial results and business trends. It supplements the audited financial statements but does not form part of them. The document is about 15,000 characters long, indicating it is a substantive report, not a brief announcement. Therefore, this document fits the category of Management Reports (MDA).
2021-03-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CEO of BMGB Capital Corp. regarding the interim financial report and interim MD&A for the period ended December 31, 2020. It is titled 'Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate' and contains statements about the review and fair presentation of the interim filings. The document does not contain actual financial data or detailed financial statements but is a certification letter confirming the accuracy and completeness of the interim filings. According to the CERTIFICATION RULE, such officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is under 5,000 characters and is primarily a certification letter, not the report itself.
2021-03-02 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Statements' for the six months ended December 31, 2020, and is unaudited. It contains detailed financial statements including statements of financial position, operations and comprehensive loss, changes in shareholders' equity, and cash flows. The notes describe accounting policies and share capital details. The presence of IAS 34 compliance and the interim period financial data confirms this is a comprehensive interim financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-03-02 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the six months ended December 31, 2020, dated March 1, 2021. It contains detailed discussion of the company's financial position, results of operations, liquidity, capital resources, and outlook for the six-month interim period. It references condensed interim financial statements prepared under IFRS and includes substantive financial data and analysis for the half-year period. The presence of forward-looking statements, discussion of quarterly results, and detailed financial metrics confirms this is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-03-02 English
Other.pdf
M&A Activity Classification · 95% confidence The document is titled 'Share Exchange Agreement' and details a purchase of shares transaction between NAVCO Pharmaceuticals Limited and BMGB Capital Corp. It includes detailed legal terms, definitions, representations, warranties, covenants, and closing arrangements typical of a share purchase or exchange agreement. There is no indication that this is a financial report, earnings release, or regulatory filing. Instead, it is a legal agreement related to a transaction involving shares. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under 'M&A Activity' (Code: TAR). This document fits that category as it is a share exchange agreement, a form of merger/acquisition transaction document.
2021-01-19 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and provides detailed information about a material change involving a qualifying transaction and private placement by BMGB Capital Corp. It includes specifics about share issuance, transaction terms, regulatory approvals, and trading status. The document is 4132 characters long, which is relatively short and resembles a regulatory announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis. The content aligns with a material change report filed with securities commissions, which is a type of regulatory filing. Therefore, the document fits best under the 'Regulatory Filings' category (RNS) as it is a formal disclosure of a material event rather than a full report or announcement of a report publication.
2021-01-19 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.